Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Prevention of the Paracentesis-Induced Circulatory Dysfunction (PICD) in Cirrhosis: Is the SPA Treatment Worthwhile?

Hoefs JC.

Dig Dis Sci. 2016 Oct;61(10):2773-2775. doi: 10.1007/s10620-016-4248-5. Epub 2016 Aug 23. No abstract available.

PMID:
27553694
2.

A Phase II Randomized, Controlled Trial of S-Adenosylmethionine in Reducing Serum α-Fetoprotein in Patients with Hepatitis C Cirrhosis and Elevated AFP.

Morgan TR, Osann K, Bottiglieri T, Pimstone N, Hoefs JC, Hu KQ, Hassanein T, Boyer TD, Kong L, Chen WP, Richmond E, Gonzalez R, Rodriguez LM, Meyskens FL.

Cancer Prev Res (Phila). 2015 Sep;8(9):864-72. doi: 10.1158/1940-6207.CAPR-15-0029. Epub 2015 Jun 30.

3.

Functional elements associated with hepatic regeneration in living donors after right hepatic lobectomy.

Everson GT, Hoefs JC, Niemann CU, Olthoff KM, Dupuis R, Lauriski S, Herman A, Milne N, Gillespie BW, Goodrich NP, Everhart JE.

Liver Transpl. 2013 Mar;19(3):292-304. doi: 10.1002/lt.23592.

4.

Very low viral load (VLVL) relapse following treatment of naïve patients with chronic hepatitis C.

Hoefs JC, Aulakh VS, Ilagan BJ.

Dig Dis Sci. 2012 Jan;57(1):243-9. doi: 10.1007/s10620-011-1973-7. Epub 2011 Dec 4.

PMID:
22139019
5.

Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial.

Everson GT, Shiffman ML, Hoefs JC, Morgan TR, Sterling RK, Wagner DA, Lauriski S, Curto TM, Stoddard A, Wright EC; HALT-C Trial Group.

Hepatology. 2012 Apr;55(4):1019-29. doi: 10.1002/hep.24752. Epub 2012 Mar 1.

6.

Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C.

Sterling RK, Wright EC, Morgan TR, Seeff LB, Hoefs JC, Di Bisceglie AM, Dienstag JL, Lok AS.

Am J Gastroenterol. 2012 Jan;107(1):64-74. doi: 10.1038/ajg.2011.312. Epub 2011 Sep 20.

7.

Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial.

Hoefs JC, Shiffman ML, Goodman ZD, Kleiner DE, Dienstag JL, Stoddard AM; HALT-C Trial Group.

Gastroenterology. 2011 Sep;141(3):900-908.e1-2. doi: 10.1053/j.gastro.2011.06.007. Epub 2011 Jun 12.

8.

Testing beneficial therapy in human cirrhosis using animal models of cirrhosis.

Hoefs JC, Morgan T, Ilagan BJ.

Dig Dis Sci. 2011 Apr;56(4):929-30. doi: 10.1007/s10620-011-1578-1. No abstract available.

9.

Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial.

Everhart JE, Wright EC, Goodman ZD, Dienstag JL, Hoefs JC, Kleiner DE, Ghany MG, Mills AS, Nash SR, Govindarajan S, Rogers TE, Greenson JK, Brunt EM, Bonkovsky HL, Morishima C, Litman HJ; HALT-C Trial Group.

Hepatology. 2010 Feb;51(2):585-94. doi: 10.1002/hep.23315.

10.

Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma.

Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, Morgan TR, Kim HY, Lee WM, Bonkovsky HL, Dienstag JL; HALT-C Trial Group.

Gastroenterology. 2010 Feb;138(2):493-502. doi: 10.1053/j.gastro.2009.10.031. Epub 2009 Oct 20.

11.

Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.

Shiffman ML, Morishima C, Dienstag JL, Lindsay KL, Hoefs JC, Lee WM, Wright EC, Naishadham D, Everson GT, Lok AS, Di Bisceglie AM, Bonkovsky HL, Ghany MG; HALT-C Trial Group.

Gastroenterology. 2009 Dec;137(6):1986-94. doi: 10.1053/j.gastro.2009.08.067. Epub 2009 Sep 10. Erratum in: Gastroenterology. 2010 Mar;138(3):1215.

12.

Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C.

Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML, Lee WM, Lok AS, Di Bisceglie AM, Bonkovsky HL, Hoefs JC, Dienstag JL, Morishima C, Abnet CC, Sinha R; HALT-C Trial Group.

Hepatology. 2009 Nov;50(5):1360-9. doi: 10.1002/hep.23162.

13.

Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.

Lok AS, Everhart JE, Chung RT, Kim HY, Everson GT, Hoefs JC, Greenson JK, Sterling RK, Lindsay KL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Ghany MG, Morishima C; HALT-C Trial Group.

Hepatology. 2009 Jun;49(6):1828-37. doi: 10.1002/hep.22865.

14.

Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT-C trial.

Everson GT, Shiffman ML, Hoefs JC, Morgan TR, Sterling RK, Wagner DA, Desanto JL, Curto TM, Wright EC; HALT-C Trial Group.

Aliment Pharmacol Ther. 2009 Mar 1;29(5):589-601. doi: 10.1111/j.1365-2036.2008.03908.x. Epub 2008 Dec 1.

15.

The spectrum of hepatic functional impairment in compensated chronic hepatitis C: results from the Hepatitis C Anti-viral Long-term Treatment against Cirrhosis Trial.

Everson GT, Shiffman ML, Morgan TR, Hoefs JC, Sterling RK, Wagner DA, Kulig CC, Curto TM, Wright EC; Halt-C Trial Group.

Aliment Pharmacol Ther. 2008 May;27(9):798-809. doi: 10.1111/j.1365-2036.2008.03639.x. Epub 2008 Feb 7.

16.

Seventy-two weeks of peginterferon and ribavirin for patients with partial early virologic response?

Hoefs JC, Morgan TR.

Hepatology. 2007 Dec;46(6):1671-4. No abstract available.

PMID:
18046713
17.

Portal-systemic shunting in patients with fibrosis or cirrhosis due to chronic hepatitis C: the minimal model for measuring cholate clearances and shunt.

Everson GT, Martucci MA, Shiffman ML, Sterling RK, Morgan TR, Hoefs JC; HALT-C trial group.

Aliment Pharmacol Ther. 2007 Aug 1;26(3):401-10.

18.

Noninvasive evaluation of liver disease severity.

Hoefs JC, Chen PT, Lizotte P.

Clin Liver Dis. 2006 Aug;10(3):535-62, viii-ix. Review.

PMID:
17162227
19.

Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial.

Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, Lok AS, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Morishima C; HALT-C Trial Group.

Hepatology. 2006 Dec;44(6):1675-84.

20.

Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C.

Bonkovsky HL, Naishadham D, Lambrecht RW, Chung RT, Hoefs JC, Nash SR, Rogers TE, Banner BF, Sterling RK, Donovan JA, Fontana RJ, Di Bisceglie AM, Ghany MG, Morishima C; HALT-C Trial Group.

Gastroenterology. 2006 Nov;131(5):1440-51. Epub 2006 Aug 18.

PMID:
17101320
21.

Factors affecting the quantitative liver-spleen scan in normal individuals.

Hoefs JC, Sheikh MY, Guerrero H, Milne N.

Dig Dis Sci. 2005 Feb;50(2):283-9.

PMID:
15745086
22.

Precore mutant hepatitis B reactivation after treatment with CHOP-rituximab.

Zell JA, Yoon EJ, Ignatius Ou SH, Hoefs JC, Chang JC.

Anticancer Drugs. 2005 Jan;16(1):83-5.

PMID:
15613909
23.

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, Goodman ZD, Laughlin M, Yao R, Albrecht JK; Hepatitis Interventional Therapy Group.

Hepatology. 2001 Aug;34(2):395-403.

PMID:
11481625
24.

Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: effect of baseline viral concentration. Consensus Interferon Study Group.

Jensen DM, Krawitt EL, Keeffe EB, Hollinger FB, James SP, Mullen K, Everson GT, Hoefs JC, Fromm H, Black M, Foust RT, Pimstone NR, Heathcote EJ, Albert D.

Am J Gastroenterol. 1999 Dec;94(12):3583-8.

PMID:
10606323
25.

A novel, simple method of functional spleen volume calculation by liver-spleen scan.

Hoefs JC, Wang FW, Lilien DL, Walker B, Kanel G.

J Nucl Med. 1999 Oct;40(10):1745-55.

26.

Functional measurement of nonfibrotic hepatic mass in cirrhotic patients.

Hoefs JC, Wang F, Kanel G.

Am J Gastroenterol. 1997 Nov;92(11):2054-8.

PMID:
9362191
27.

Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group.

Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs JC, Keeffe EB, Hollinger FB, Hathcote EJ, White H, Foust RT, Jensen DM, Krawitt EL, Fromm H, Black M, Blatt LM, Klein M, Lubina J.

Hepatology. 1997 Sep;26(3):747-54.

PMID:
9303508
28.

The liver-spleen scan as a quantitative liver function test: correlation with liver severity at peritoneoscopy.

Hoefs JC, Wang F, Kanel G, Braunstein P.

Hepatology. 1995 Oct;22(4 Pt 1):1113-21.

PMID:
7557859
29.

Raising the dose of interferon does not improve the response in chronic hepatitis C.

Fong TL, Morgan TR, Phan CG, Hoefs JC.

J Clin Gastroenterol. 1995 Jan;20(1):42-4.

PMID:
7884177
31.

Diagnostic paracentesis.

Hoefs JC, Jonas GM.

Adv Intern Med. 1992;37:391-409. Review. No abstract available.

PMID:
1558004
32.

Spontaneous bacterial peritonitis: prevention and therapy.

Hoefs JC.

Hepatology. 1990 Oct;12(4 Pt 1):776-81. No abstract available.

PMID:
2210680
33.

Diagnosis and hemodynamic assessment of portal hypertension.

Hoefs JC, Jonas GM, Sarfeh IJ.

Surg Clin North Am. 1990 Apr;70(2):267-89. Review.

PMID:
2181705
34.

Diagnostic paracentesis. A potent clinical tool.

Hoefs JC.

Gastroenterology. 1990 Jan;98(1):230-6. Review.

PMID:
2403429
35.

Measurement of portal shunting in dogs.

Hoefs JC.

Am J Gastroenterol. 1989 Mar;84(3):296-301.

PMID:
2919586
36.

Ascitic fluid analysis in malignancy-related ascites.

Runyon BA, Hoefs JC, Morgan TR.

Hepatology. 1988 Sep-Oct;8(5):1104-9.

PMID:
3417231
37.

Hepatofugal portal flow in cirrhosis: observations on hepatic hemodynamics and the nature of the arterioportal communications.

Rector WG Jr, Hoefs JC, Hossack KF, Everson GT.

Hepatology. 1988 Jan-Feb;8(1):16-20.

PMID:
3338703
38.

Glucose intolerance and hepatic, biliary tract and pancreatic dysfunction.

Glick ME, Hoefs JC, Meshkinpour H.

Dig Dis. 1987;5(2):78-96. No abstract available.

PMID:
3301091
39.

Polymicrobial bacterascites. A unique entity in the spectrum of infected ascitic fluid.

Runyon BA, Hoefs JC, Canawati HN.

Arch Intern Med. 1986 Nov;146(11):2173-5.

PMID:
3778046
40.

Estimation of acoustic attenuation in liver using one megabyte of data and the zero-crossings technique.

Duerinckx AJ, Ferrari LA, Hoefs JC, Sankar PV, Fleming D, Cole-Bueglet C.

Ultrasonics. 1986 Nov;24(6):325-32.

PMID:
3535199
41.

Noninvasive evaluation of hepatic fibrosis using frequency demodulation of ultrasound signals.

Hoefs JC, Aufrichtig D, Lottenberg S, Kanel GC, Donner BS, Ferrari LA, Leeman S, Friedenberg RM.

Dig Dis Sci. 1986 Oct;31(10):1046-55.

PMID:
3530672
43.

Peritoneal lymphomatosis with ascites. A characterization.

Runyon BA, Hoefs JC.

Arch Intern Med. 1986 May;146(5):887-8.

PMID:
3963980
44.

Ascites kinetics in cirrhosis: relationship to plasma-ascites hydrostatic-oncotic balance and intensity of renal sodium retention.

Rector WG Jr, Ibarra F, Openshaw K, Hoefs JC.

J Lab Clin Med. 1986 May;107(5):412-9.

PMID:
3701188
45.

Spontaneous bacterial peritonitis.

Hoefs JC, Runyon BA.

Dis Mon. 1985 Sep;31(9):1-48. Review.

PMID:
3899555
46.
47.
48.

Mechanism for the abnormal liver scan in acute alcoholic liver injury.

Hoefs JC, Green G, Reynolds TB, Sakimura I.

Am J Gastroenterol. 1984 Dec;79(12):950-8.

PMID:
6507421
49.

Culture-negative neutrocytic ascites: a variant of spontaneous bacterial peritonitis.

Runyon BA, Hoefs JC.

Hepatology. 1984 Nov-Dec;4(6):1209-11.

PMID:
6500513
50.

Is the concept of "exudative" ascites useful?

Runyon BA, Hoefs JC.

Hepatology. 1984 Sep-Oct;4(5):982. No abstract available.

PMID:
6479863

Supplemental Content

Loading ...
Support Center